This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

An in depth review of our latest understanding of the molecular events that regulate cell death and those molecules that provide targets for developing agonists or antagonists to modulate death signaling for therapeutic purposes. The authors focus on the extrinsic system of death receptors, their regulation and function, and their abnormalities in cancer. Topics of particular interest include resistance to apoptosis, TRAIL signaling, death receptors in embryonic development, mechanisms of caspase activation, and death receptor mutations in cancer. Additional chapters address death signaling in melanoma, synthetic retinoids and death receptors, the role of p53 in death receptor regulation, immune suppression of cancer, and combination therapy with death ligands.

This book is about "Angiogenesis". A process in which new vasculature is formed from pre-existing capillaries. Angiogenesis process is associated with the proliferation and growth of both physiologically normal and neoplastic tissues, through the formation of vascular supply, essential for delivering growth requirements such as oxygen and nutrients. The book describes more than 100 genes and their key regulatory functions in the context of normal healthy condition, disease and malignancy, cancer proliferation and progression. New insights into the role of angiogenesis and the therapeutic inhibition of its regulators are investigated, due to the great potential for exploitation in the development of a novel treatment for cancer. New scientists, junior researchers and biomedical science students will find this book an invaluable introductory reference to their insight about angiogenesis and angiogenic role of more than 100 angiogenes and their role in healthy, disease and malignant conditions.

Melanoma is one of the most types of cancer. When melanoma is detected at an early stage, treatment is highly successful, but outcomes can be poor when the disease is advanced. There has been significant progress in our understanding of the molecular biology, genetics, and immunology of melanoma over the past decade. This has been accompanied by rapid advances in therapeutic strategies for patients with melanoma. This book provides the clinician and the researcher with a broad understanding of the molecular and cellular pathogenesis of melanoma, explores the clinical characteristics and criteria for clinical and pathological staging of the disease, and provides an overview of current and evolving treatment strategies in the adjuvant, metastatic, and preventive settings. The treatment of special populations and rare variants of melanoma that often present particular clinical challenges is also covered. Authored by international experts in melanoma biology and clinical management, this volume concisely explains how to diagnose, treat, and prevent melanoma while reviewing advances in basic science and providing an overview of innovative approaches still under development.

The hematopoietic system plays roles that are crucial for survival of the host: delivery of oxygen to tissues, arrest of accidental blood leaking from blood vessels, and fending off of invading microbes by humoral, cell-mediated, and phagocytic immunity. The activity of the hematopoietic system is staggering: daily, a normal adult produces approximately 2.5 billion erythrocytes, 2.5 billion platelets, and 1 billion granulocytes per kilogram of body weight. This production is adjusted in a timely fashion to changes in actual needs and can vary from nearly none to many times the normal rate depending on needs which vary from day to day, or even minute to minute. In response to a variety of stimuli, the cellular components of the blood are promptly increased or decreased in production to maintain appropriate numbers to optimally protect the host from hypoxia, infection, and hemorrhage. How does this all happen and happen without over or under responding? There has been extraordinary growth in our understanding ofhematopoiesis over the last two decades. Occupying center stage is the pluripotent stern cell and its progeny. Hematopoietic stern cells have been characterized by their capacity for self renewal and their ability to proliferate and differentiate along multiple lineages. Few in number, the stern cell gives rise to all circulating neutrophils, erythrocytes, lymphoid cells, and platelets. In hematopoietic transplantation, the stern cell is capable of restoring long-term hematopoiesis in a lethally irradiated host.

Rhim and Kremer s state-of-the-art volume on "Human Cell Transformation: Role of Stem Cells and the Microenvironment" highlights the latest findings on the current state of human cell transformation model systems and provides the insight into the molecular and cellular changes involved in the conversion of normal cells to neoplastic cells.

Chapters cover all recently developed novel human cell models. In addition, the rapidly growing fields of knowledge regarding not only stem cells in cancer progression, but also the role of the microenvironments in human carcinogenesis are discussed. A wealth of topics is presented including:

. Derivation of epithelial, fibroblastic, and hematopoietic "in vitro" model systems

. Oncogenes

. Tumor suppressor genes

. Viral transformation

. "In vitro" model systems for viral, chemical and radiation carcinogenesis

. Cell aging

. The multistep nature of human carcinogenesis. The role of stem cells and the microenvironment in tumorigenesis

. The genes involved in multistep carcinogenesis

Unique in both scope and focus devoted solely to human cell transformation systems "Human Cell Transformation: Role of Stem Cells and the Microenvironment" provides unparalleled, in-depth coverage for cancer researchers, cell and molecular biologists, hematologists, virologists, and workers in related fields.

Essential reading for everyone who needs to be kept up-to-date in this fast-paced area

Features

O Multistep models

O Breast cancer/Stem cells

O Prostate cancer/Stem cells

O Multistep / Genes"

A deeply moving story about the courage of a man diagnosed with a rare form of lymphoma and his wife's realization that God's love was the one thing she could count on.

Since their first description in 1875, Merkel cells have remained an elusive cell type. Their origin as well as their classification as mechanoreceptors have been a matter of controversy and intense discussion. The peptidergic granules in these cells are suggestive of neuroendocrine functions, but their discovery has raised additional questions regarding Merkel cell function. Essential aspects of structure, development and function of normal Merkel cells and Merkel cell carcinoma are presented in short chapters, providing concise and up-to date information on this fascinating cell type.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

This book provides the most up-to-date review of the simian virus 40 (SV40) minichromosome as a model for the mammalian chromosome in studies of DNA replication. It focuses on disruption of DNA replication by anticancer drugs and DNA-damaging agents. There is a strong emphasis on the unique advantages of SV40 as an experimental system for the analysis of these classes of anticancer drug mechanisms. The new high-resolution gel electrophoresis methods for the analysis of SV40 DNA replication are covered in detail to aid readers in designing and interpreting similar experiments.
Key Features
* Presents unique advantages of SV40 as an experimental system for the study of classes of anticancer drugs
* Details new high-resolution gel electrophoresis methods for the analysis of SV40 DNA replication
* Provides details to help the reader design and interpret similar experiments

Technical and Biological Components of Marrow Transplantation presents up to date information on the scientific and technological advances that will extend and improve the clinical application of bone marrow transplantation. The book includes the latest information on chronic myeloid leukemia and thalassemia; advances in supportive care: cytokines and progenitor expansion; and cord stem cell technology. Soon more of patients will receive marrow transplants as part of the therapy for solid tumors and metabolic disease than for the treatment of hematologic disease. The contributors to this volume describe some of these applications, hinting at yet further, exciting possibilities.

This book describes important developments and emerging trends in experimental and clinical cancer gene therapy. It reflects the tremendous advances made over recent years with respect to immunogenes, suicide genes and gene correction therapies, as well as in gene suppression and miRNA therapies. Many of the described strategies focus on the generation of more efficient and specific means of attack at known and novel cellular targets associated with tumor development and progression. The book also details parallel improvements in vector design, vector delivery, and therapeutic efficacy. It offers readers a stimulating, broad overview of advances in the field, linking experimental strategies to their clinical applications.

This volume provides an interdisciplinary perspective of applying Next Generation Sequencing (NGS) technology to cancer research. It aims to systematically introduce the concept of NGS, a variety of NGS platforms and their practical implications in cancer biology.This unique and comprehensive text will integrate the unprecedented NGS technology into various cancer research projects as opposed to most books which offer a detailed description of the technology. This volume will present true experimental results with concrete data processing pipelines, discuss the bottleneck of each platform for real project in cancer research. In additional, single cancer cell sequencing as the proof of concept will be introduced in this book, along with cutting-edge information provided will help the intended audience to develop a comprehensive understanding of the NGS technology and practical whole genome sequencing data analysis and rapidly translate into their own research, specifically in the field of cancer biology.

This volume constitutes, in part, the proceedings of the Hong Kong Conference on "Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury" held in Hong Kong in October 1995. It contains papers by the symposium speakers, as well as poster contributions from researchers in this field. Since the discovery of "PROSTAGLANDIN-LIKE' substances 60 years ago. much has been learned. EICOSANOID is the new term that is used to include prostaglandins. thromboxanes, leukotrienes, lipoxins, isoprostanes, depoxilins, hydroxy acids, epoxy and hydroperoxy fatty acids. The conference focussed on recent development in underatanding the role of EICOSANOIDS in inflammation, cancer, and radiation damage. At the confer- ence, we also highlighted advances in newly developing areas such as "NO," "A POP- TOSIS and "ANANDAMIDE." The discovery of the structures of genes that encode several key enzymes and receptors of the Eicosanoid cascade, has allowed us to include reports in the "Alteration of the Gene Expression" section that reflects the most recent de- velopments in regulation for PGH-synthase and lipoxygenases. The editors are convinced that this volume will be an up-to-date and useful reference for investigators in both basic and clinical research.

In 1971, J. Folkman published in the New England Journal of Medicine a hypothesis that tumor growth is angiogenesis-dependent. Folkman introduced the concept that tumors probably secrete diffusible molecules that could stimulate the growth of new blood vessels toward the tumor and that the resulting tumor neovascularization could conceivably be prevented or interrupted by angiogenesis inhibitors. Solid and haematological tumors consist of an avascular and a subsequent vascular phase. Assuming that this depends on the release of angiogenic factors, acquisition of angiogenic capability can be seen as an expression of progression from neoplastic transformation to tumor growth and metastasis.

Beginning in the 1980 s, the biopharmaceutical industry began exploiting the field of antiangiogenesis for creating new therapeutic compounds for modulating new blood vessels in tumor growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF monoclonal antibody, was the first angiogenesis inhibitor approved by the Food and Drug Administration for the treatment of colorectal cancer. At present, it has been estimated that over 20,000 cancer patients worldwide have received experimental form of antiangiogenic therapy.

This book offers a historical account of the relevant literature. It also emphasizes the crucial and paradigmatic role of angiogenesis as a biological process and the significance of antiangiogenic approach for the treatment of tumors."

Breast cancer is the most common cancer in females that accounts for highest cancer specific deaths worldwide. In the last few decades research has proven that breast cancer can be treated if diagnosed at early stages and proper therapeutic strategy is adopted. Omics-based recent approaches have unveiled the molecular mechanism behind the breast tumorigenesis and aid in identification of next-generation molecular markers for early diagnosis, prognosis, and even the effective targeted therapy. Significant development has taken place in the field of omics in breast cancer in the last decade. The most promising omics approaches and their outcomes in breast cancer have been presented in this book for the first time. The book covers omics technologies and budding fields such as breast cancer miRNA, lipidomics, epigenomics, proteomics, nutrigenomics, stem cell, pharmacogenomics and personalized medicine, and many more along with conventional topics such as breast cancer management etc. It is a research-based reference book useful for clinician-scientists, researchers, geneticists and health care industries involved in various aspects of breast cancer. The book will also be useful for students of biomedicine, pathology, and pharmacy.

Leading transplant physicians critically review and interpret twenty-one key clinical challenges in bone marrow/hematopoietic cell transplantation, and offer their best personal recommendations for treatment. Topics range from transplant strategies to complications of bone marrow transplantation, including a discussion of the indications, benefits, and the risks for a variety of leukemias, lymphomas, and solid tumors. The authors debate such contentious issues as the appropriateness of transplants in older patients, how many stem cells are sufficient for engraftment, and the pros and cons of umbilical cord blood transplantation. Up-to-date and clinically focused, Current Controversies in Bone Marrow Transplantation offers clinical oncologists, hematology/oncology fellows in training, and residents in internal medicine today's best ready reference and management guide for all their critical oncologic problems arising from the use of bone marrow/stem cell transplantation.

The discovery of microRNAs and its role as gene expression regulators in human carcinogenesis represents one of the most important scientific achievements of the last decade. More recently, other non-coding RNAs have been discovered and its implications in cancer are emerging as well, suggesting a broader than anticipated involvement of the non-coding genome in cancer. Moreover, completely new and unexpected functions for microRNAs are being revealed, leading to the identification of new anticancer molecular targets. This book represents a comprehensive guide on non-coding RNAs and cancer, spanning from its role as cancer biomarkers, to providing the most useful bioinformatic tools, to presenting some of the most relevant discoveries, which indicates how these fascinating molecules act as fine orchestrators of cancer biology.

Creating clinical guidelines is a modern trend. Published studies pertaining to a given theme are collected, their credibility evaluated, and then treatment options in the form of evidence-based guidelines are offered. There are a number of guidelines for the treatment of thyroid tumors that have established positions in clinical practice in North America and in Western European countries. In Japan, however, where radioisotope facilities are of limited availability, treatment plans for differentiated thyroid cancer differ considerably from those of America and Europe, and the associated clinical guidelines need modification before they can be adopted. In addition, although thyroid tumor is a common disease in endocrine practice, its management can differ even among specialists. Thus, a Japanese clinical guideline for the treatment of thyroid tumor was desired by many clinicians. As a combination of evidence-based and consensus-based guidelines for the treatment of thyroid tumor, this book offers alternatives to conventional approaches in the West. Ultimately, the authors hope the guideline will lead to the best possible treatment for patients all over the world in the not-distant future.

Leland H. Hartwell Director, Fred Hutchinson Cancer Research Center, Nobel Laureate for Medicine, 2001 Yeast has proved to be the most useful single-celled organism for studying the fundamental aspects of cell biology. Resources are now available for yeast that greatly simplify and empower new investigations, like the presence of strains with each gene deleted, each protein tagged and databases on protein-protein interactions, gene regulation, and subcellular protein location. A powerful combination of genetics, cell biology, and biochemistry employed by thousands of yeast researchers has unraveled the complexities of numerous cellular processes from mitosis to secretion and even uncovered new insights into prion diseases and the role of prions in normal biology. These insights have proven, time and again, to foretell the roles of proteins and pathways in human cells. The collection of articles in this volume explores the use of yeast in pathway analysis and drug discovery. Yeast has, of course, supplied mankind's most ubiquitous drug for thousands of years. In one aspect, the role of yeast in drug discovery is much like the role of yeast in other areas of biology. Yeast offers the power of genetics and a repetoire of resources available in no other organism. Using yeast in the study of drug targets and metabolism can help to make a science of what has been largely an empirical activity. A science of drug discovery would permit rigorous answers to important questions.

This book provides a comprehensive coverage and a succinct overview of the current status of supportive cancer care with Chinese medicine written by leading experts in the field. The chapters coherently present an overview on the major treatment approaches of Chinese medicine and progresses made with different important aspects on supportive cancer care with acupuncture, herbal therapy and qigong. Moreover, there are reviews on the evidences and efficacies of Chinese medicine for controlling radiation-induced injuries, chemotherapy-related side effects, as well as pain control with Chinese medicine. In order to provide information from basic science at the bench to the patient's bedside, modern researches and clinical trials would be overviewed so as to give an up-to-date and realistic evaluation of a therapy's utility for cancer patients. It is also worth noting that toxicology, safety and herb-drug interactions are the main concerns of using Chinese medicine combined with western medicine. A chapter will expound on these issues and there will also be chapters discussing integrative Chinese and Western medicine, as well as cancer prevention with Chinese medicine. This book presents state-of-the-art knowledge on supportive cancer care with Chinese medicine, which will appeal to anyone involved in cancer care. This is a precious book for all types of readers, including but not limited to oncologists, cancer researchers, pharmacologists, pharmaceutical specialists, traditional Chinese medicine practitioners, Chinese medicine educators, medicine postgraduates and undergraduates, cancer caregivers, cancer survivors, and family members of cancer patients who want to expand their knowledge in supportive cancer care.

Endocrine Neoplasia is a comprehensive, updated, and clearly-written text covering the diseases for which endocrine surgical expertise is often needed. We look towards advances in the science and the art of endocrine surgery to continuously improve outcomes for our patients. The goal of this text was to provide a detailed description of both the underlying science of disease as well as the art of clinical management.

The book is divided into five sections addressing neoplasms of the thyroid, parathyroid, adrenal gland, neuroendocrine pancreas, and multiple endocrine neoplasia. Experts from the United States, Canada, and Australia have contributed chapters addressing both the biology of endocrine tumors and the clinical management of disease. Recent discoveries regarding the genetic underpinnings of disease are highlighted. Updated consensus guidelines were used for clinical recommendations. The management of complex and often confusing clinical problems is discussed in detail.

Multiple myeloma is the second most common hematologic malignancy and c- rently affects approximately 50,000 people in the United States. Each year about 20,000 people are diagnosed with myeloma. Although new treatments have been developed, which signi?cantly prolong the survival of patients, myeloma bone d- ease still remains a major cause of severe morbidity and increased mortality in patients with myeloma. Myeloma bone disease is characterized by "punched out" lytic lesions caused by increased osteoclastic bone destruction accompanied by suppressed or even absent osteoblast activity. Advances in our understanding of both the pathophysiology of myeloma bone disease and the development of novel agents that target speci?c pathways involved in both the increased osteoclast f- mation and the suppressed osteoblast activity in myeloma provide new hope for these patients. The treatment of myeloma bone disease was revolutionized by cl- ical trials that demonstrated the signi?cant bene?t of intravenous bisphosphonate therapy in patients with myeloma bone disease. With the identi?cation of many of the cytokines and chemokines involved in myeloma bone disease, novel th- apies such as denosumab that blocks RANKL activity, anti-DKK1, which targets the inhibition of osteoblast activity by blocking Wnt signaling inhibition, and the potential anabolic effects of agents such as bortezomib and activin have greatly improved our potential to block the progression or reverse myeloma bone disease.